Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Allogeneic HSCT in High-Risk AML
NCT00188136Phase 2Completed
- Sponsor
- University Hospital Carl Gustav Carus
- Start
- Aug 2002
- Primary completion
- Jul 2010
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, melphalan, antithymocyte globulin in acute myeloid leukemia (AML), sponsored by University Hospital Carl Gustav Carus. Started Aug 2002; status: completed.
02
Drugs
fludarabinemelphalanantithymocyte globulin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00188136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00188136.